At #ATS2025 we’re sharing our latest research as we continue in our work reduce the impact that exacerbations can have on the future lung health of patients with conditions like #asthma and #COPD. Read more on why it’s important to prevent exacerbations.

#News for #Investors and #Media . The Japan Ministry of Health, Labour and Welfare (MHLW) has approved one of our blood cancer therapies. Find more information here:

We’re at #ATS2025 to share our latest research from across 40 abstracts from our respiratory portfolio. Court Horncastle, SVP, US Specialty Business Unit head, shares his thoughts on why ATS is so important to getting ahead of respiratory disease.

In advance of #ATS2025 Kaivan Khavandi shares his thoughts on how we are applying our expertise to deliver the next generation standard of care and help millions of patients with respiratory conditions. 👉

#News for #investors and #media: Today we announced an agreement with Boston Pharmaceuticals to further strengthen our hepatology pipeline in steatotic liver disease.

Congratulations to our CEO Emma Walmsley on being named in the 2025 #TIME100HEALTH list, which recognises the most influential leaders in health each year. See the full list here: #Time100

#News for #investors and #media: New data has been presented at #EASL2025 on our research into cholestatic pruritus (relentless itch) associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease. More information:

Years of innovation have expanded the menu of preventative medicines available but science alone isn’t enough to make sure people have access to them. Here, @ProfHeidiLarson, anthropologist and co-founder of the Global Listening Project, explains why 👇

The race against malaria is on – find out why, and how, we’re accelerating research to help #ChangeTheTrajectory of the disease, here 👇.

“It took 35 years to even get to the point where malaria vaccines are available. And now we’re excited to be researching a second-generation vaccine”. Katie Ewer, GSK Malaria Vaccine Project Leader explains to The Telegraph that our research aims to work at a different stage of

#News for #investors and #media: At #ATS2025, we’ll be presenting data from 40+ abstracts on our work to redefine the future of respiratory care. Learn more:

#News for #investors and #media:. Today we have announced the full results of a phase III trial of one of our biologics in patients with chronic obstructive pulmonary disease (COPD) have been published in the New England Journal of Medicine. Learn more at:

Explore the key highlights from our Q1 2025 performance. More information for media and investors: $GSK.

#Investors: Join our CEO Emma Walmsley and other members of our leadership team for our Q1 2025 results webcast at 12:00 BST, 07:00 EST. $GSK

Our CEO Emma Walmsley announces our strong Q1 2025 performance, demonstrating the quality, strength and resilience of our portfolio. More information for media and investors: .$GSK #FYResults

#Investors and #Media: Read our cautionary statement regarding forward-looking statements: Definitions and reconciliations for non-IFRS measures are included in our Q1 2025 results press release: CER% represents constant exchange.

We’re announcing our Q1 2025 results tomorrow at 0700 BST, 0200 EST. $GSK

#News for #investors and #media: . Two of our vaccines have received new recommendations from the US Advisory Committee on Immunization Practices (ACIP). These recommendations will be reviewed for official adoption. Learn more:

#News for #Investors and #Media. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed one of our blood cancer therapies. More information for media and investors: